Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Phase 1
Completed
- Conditions
- Follicular Lymphoma, Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02603445
- Locations
- 🇩🇪
Novartis Investigative Site, Mainz, Germany
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1053
- Registration Number
- NCT02603393
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
- First Posted Date
- 2015-11-10
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT02601378
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇪🇸Novartis Investigative Site, Madrid, Spain
Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.
Phase 3
Terminated
- Conditions
- Myelofibrosis With High Molecular Risk Mutations
- Interventions
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT02598297
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT02595970
- Locations
- 🇫🇷
Novartis Investigative Site, Toulouse Cedex, France
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive (COPD)
- Interventions
- Device: Breezhaler®Device: Handihaler®Device: Ellipta®
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 97
- Registration Number
- NCT02596009
- Locations
- 🇦🇷
Novartis Investigative Site, Ciudad Autonoma de Bs As, Argentina
Global Non-interventional Heart Failure Disease Registry
Terminated
- Conditions
- Acute Heart Failure
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 18805
- Registration Number
- NCT02595814
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 233
- Registration Number
- NCT02584933
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Loma Linda University, Loma Linda, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Head to Head Study of Anti-VEGF Treatment.
Phase 4
Completed
- Conditions
- Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02577107
- Locations
- 🇨🇳
Novartis Investigative Site, Chengdu, Sichuan, China
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
Phase 2
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: PlaceboDrug: CNP520
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 124
- Registration Number
- NCT02576639
- Locations
- 🇬🇧
Novartis Investigative Site, Mid Glamorgan, United Kingdom